Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab [(Opdivo)], an anti-PD-1 antibody, in these patients. Methods: This was a multicentre, … [Read more...]
Drug Combo Promising in Rare Mesothelioma
A combination of atezolizumab (Tecentriq) and bevacizumab appeared effective and safe in patients with advanced malignant peritoneal mesothelioma, according to results from a small single-arm trial. The combination achieved an objective response rate (ORR) of 40% in patients who had progressed on or were resistant to prior platinum-pemetrexed … [Read more...]
Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications
Background: Malignant peritoneal mesothelioma is the most common primary peritoneal neoplasm. The only universally recognised pathological prognostic factor is histopathological subtype. Prognostic markers based on patient features and clinical stages have been disappointing. Aims: To assess the prognostic role of several clinicopathological … [Read more...]
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
AbstractMalignant mesothelioma (MM) is a treatment-resistant tumor originating in the mesothelial lining of the pleura or the abdominal cavity with very limited treatment options. More effective therapeutic approaches are urgently needed to improve the poor prognosis of MM patients. Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a … [Read more...]
Malignant Diffuse Mesothelioma in Women — A Study of 354 Cases
We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% [ pleural malignant mesothelioma ] and 22% [ peritoneal malignant mesothelioma ]. The pleural tumors consisted of 72% epithelioid, 19% biphasic, and 9% sarcomatoid variant. The … [Read more...]
Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma
Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment for peritoneal mesothelioma. In this study, we evaluated [ quality of life (QOL) ] after [ hyperthermic intraperitoneal chemotherapy (HIPEC) ] for peritoneal mesothelioma. Methods: This was a prospective study performed … [Read more...]
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience
Background: The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. Previous series suggest that multimodality treatment improves overall survival for pleural or peritoneal disease, but studies typically exclude [ … [Read more...]
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience
Background: The most common sites of malignant mesothelioma are the pleura [ i.e., pleural mesothelioma ] and peritoneum [ i.e., peritoneal mesothelioma ], but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities…. Despite limitations, this investigation is the only study to broadly examine … [Read more...]